InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,709.54
(
0.01%
)
US TECH 100
19,320.04
(
0.36%
)
Dow Jones
42,196.52
(
0.09%
)
Brent Oil
74.49
(
-0.17%
)
Bitcoin
60,792.88
(
0.28%
)
Post# of 253267
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: pharmaclown35 post# 86668

Tuesday, 12/08/2009 9:29:33 AM

Tuesday, December 08, 2009 9:29:33 AM

Post# of 253267
Celgene's MM-015 trial
Study hits its primary endpoint of improvement of PFS in patients who received MPR-R (R maintenance until progression) versus patients who received MP.
Also, stat-sig separation was seen in curves between MPR-R and MPR (R for 9 cycles without maintenance). However, there was no difference between MPR and MP.

http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=1363079&highlight=
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up